<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Orchestra Biomed Holdings Inc. — News on 6ix</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc</link>
<description>Latest news and press releases for Orchestra Biomed Holdings Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 16:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/orchestra-biomed-holdings-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a57a78dffbe2df10b206.webp</url>
<title>Orchestra Biomed Holdings Inc.</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc</link>
</image>
<item>
<title>Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-to-present-avim-therapy-clinical-and-mechanistic-data-at-hrs-2026</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-to-present-avim-therapy-clinical-and-mechanistic-data-at-hrs-2026</guid>
<pubDate>Thu, 23 Apr 2026 16:00:00 GMT</pubDate>
<description>Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate average reduction of 13.2 mmHg in office systolic blood pressure (“oSBP”)97% of patients experienced an immediate blood pressure reduction of >5 mmHg reduction in oSBP prior to randomizationAVIM Therapy demonstrated the potential to deliver immediate, substantial, and sustained reductions in blood</description>
</item>
<item>
<title>Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-reports-full-year-2025-financial-results-and-provides-fourth-quarter-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-reports-full-year-2025-financial-results-and-provides-fourth-quarter-business-update</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously</description>
</item>
<item>
<title>Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-announces-presentations-highlighting-avim-therapy-potential-impact-on-hypertensive-heart-disease-and-heart-failure-at-tht-and-crt</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-announces-presentations-highlighting-avim-therapy-potential-impact-on-hypertensive-heart-disease-and-heart-failure-at-tht-and-crt</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>NEW HOPE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company</description>
</item>
<item>
<title>Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-announces-inducement-grants-210500891</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-announces-inducement-grants-210500891</guid>
<pubDate>Fri, 13 Feb 2026 21:05:00 GMT</pubDate>
<description>NEW HOPE, Pa., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on February 12, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 120,000 shares of the Company’s common stock to</description>
</item>
<item>
<title>Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-receive-21-million-140000869</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-receive-21-million-140000869</guid>
<pubDate>Mon, 12 Jan 2026 14:00:00 GMT</pubDate>
<description>$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnoutsVivasure Medical Limited (“Vivasure”) has been a strategic holding of Orchestra BioMed since the Company’s formation NEW HOPE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing p</description>
</item>
<item>
<title>Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-announces-avim-therapy-120000663</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-announces-avim-therapy-120000663</guid>
<pubDate>Mon, 08 Dec 2025 12:00:00 GMT</pubDate>
<description>Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled hypertension in patients indicated for a pacemaker NEW HOPE, Pa., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships,</description>
</item>
<item>
<title>Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-participate-upcoming-institutional-140000733</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-participate-upcoming-institutional-140000733</guid>
<pubDate>Tue, 11 Nov 2025 14:00:00 GMT</pubDate>
<description>NEW HOPE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will participate in multiple upcoming institutional investor conferences. Details on the Company’s participation appear below: 2025 Jefferies London Healthcare Conference</description>
</item>
<item>
<title>Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-reports-third-quarter-211000253</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-reports-third-quarter-211000253</guid>
<pubDate>Mon, 10 Nov 2025 21:10:00 GMT</pubDate>
<description>Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from Medtronic and Ligand, as well as $30 million from TerumoInitiated patient enrollments in the Virtue Trial evaluating Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”) trial versus commercially available paclitaxel-coated balloon Demonstrated partnership-driven business model execution with</description>
</item>
<item>
<title>Orchestra BioMed to Host Business Update Call on November 12, 2025</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-host-business-call-130000660</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-host-business-call-130000660</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>NEW HOPE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will host a business update call on Wednesday, November 12th at 8:00 AM ET. The business update will focus on recent significant clinical, strategic and financing develop</description>
</item>
<item>
<title>Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-terumo-enter-30-120000408</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-terumo-enter-30-120000408</guid>
<pubDate>Tue, 28 Oct 2025 12:00:00 GMT</pubDate>
<description>New agreement grants Terumo Virtue SAB coronary indication right of first refusal and supersedes prior distribution agreementTerumo to pay a total of $30 million to Orchestra BioMedOrchestra BioMed retains all development and distribution rights to Virtue SAB in all indicationsOrchestra BioMed recently initiated patient enrollment for the Virtue Trial, its U.S. pivotal IDE trial of Virtue SAB in the treatment of coronary in-stent restenosis (“ISR”) NEW HOPE, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -</description>
</item>
<item>
<title>Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-announces-first-patients-130000951</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-announces-first-patients-130000951</guid>
<pubDate>Mon, 27 Oct 2025 13:00:00 GMT</pubDate>
<description>Orchestra BioMed’s Virtue® Sirolimus AngioInfusionTM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release sirolimus (“SirolimusEFRTM”)The Virtue Trial is the first U.S. investigational device exemption (“IDE”) head-to-head randomized coronary pivotal trial evaluating a sirolimus-eluting balloon versus a commercially available paclitaxel-coated balloon (AGENT™) Coronary in-stent restenosis (“ISR”), the c</description>
</item>
<item>
<title>OBIO® Introduces the Future Female Leaders in Life Sciences</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/obior-introduces-the-future-female-leaders-in-life-sciences</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/obior-introduces-the-future-female-leaders-in-life-sciences</guid>
<pubDate>Thu, 23 Oct 2025 11:00:00 GMT</pubDate>
<description>TORONTO, October 23, 2025--OBIO® is pleased to announce the women-led companies selected for the third cohort of its Women in Health Initiative (WiHI) Seed Program. Now in its third cohort, the WiHI Seed Program was established in 2023 to address the significant barriers that women-led companies face in accessing financing and wraparound supports.</description>
</item>
<item>
<title>Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-showcase-transformative-potential-120000440</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-showcase-transformative-potential-120000440</guid>
<pubDate>Thu, 09 Oct 2025 12:00:00 GMT</pubDate>
<description>Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart diseaseOrchestra BioMed and Medtronic (NYSE: MDT) have a strategic collaboration to develop and commercialize AVIM Therapy for the treatment of uncontrolled hypertension in patients indicated for a pacemaker, an estimated global population of over 750,000 patients annuallyAVIM Therapy has received FDA Breakthrough Device Designation for the tr</description>
</item>
<item>
<title>Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-presents-avim-therapy-210000958</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-presents-avim-therapy-210000958</guid>
<pubDate>Thu, 04 Sep 2025 21:00:00 GMT</pubDate>
<description>Results from long-term follow up of patients treated with atrioventricular interval modulation (“AVIM”) therapy show blood pressure-lowering effects are sustained for years after activation, reversible with no observed rebound hypertension upon deactivation of treatment, and reproducible upon reactivation following a washout periodSimultaneous peer-reviewed publication of AVIM therapy mechanistic and clinical results Orchestra BioMed and Medtronic (NYSE: MDT) have a strategic collaboration to de</description>
</item>
<item>
<title>Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-announces-publication-clinical-113000234</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-announces-publication-clinical-113000234</guid>
<pubDate>Tue, 26 Aug 2025 11:30:00 GMT</pubDate>
<description>Data from acute and chronic pressure-volume loop studies support the mechanism of action and show a favorable impact of AVIM therapy on blood pressure and cardiovascular hemodynamicsAVIM therapy drove statistically significant reductions in systolic blood pressure, intra-cardiac volumes, total peripheral resistance and stroke work, with no adverse impact on stroke volume or contractility.Orchestra BioMed and Medtronic (NYSE: MDT) have a strategic collaboration for the development of AVIM therapy</description>
</item>
<item>
<title>Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-announces-publication-avim-120000703</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-announces-publication-avim-120000703</guid>
<pubDate>Thu, 14 Aug 2025 12:00:00 GMT</pubDate>
<description>Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation (“AVIM”) therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart failure with preserved ejection fraction (“HFpEF”)Hypertension is the leading cause of diastolic dysfunction and the most common comorbidity in older patients indicated for a pacemaker NEW HOPE, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO</description>
</item>
<item>
<title>Campbellford Memorial Hospital’s New Homecare Program Frees up 14.5 Hospital Bed-Days Per Patient Through a Partnership With Gotcare and OBIO®</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/campbellford-memorial-hospitals-new-homecare-program-frees-up-145-hospital-bed-days-per-patient-through-a-partnership-with-gotcare-and-obior</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/campbellford-memorial-hospitals-new-homecare-program-frees-up-145-hospital-bed-days-per-patient-through-a-partnership-with-gotcare-and-obior</guid>
<pubDate>Wed, 13 Aug 2025 12:00:00 GMT</pubDate>
<description>CAMPBELLFORD, Ontario, August 13, 2025--Rural hospitals across Ontario face exponential challenges: patients arriving in Emergency Departments when alternative care options would be more suitable, and patients remaining hospitalized longer than medically necessary due to limited home care and long-term care support in rural areas.</description>
</item>
<item>
<title>Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-reports-second-quarter-121400906</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-reports-second-quarter-121400906</guid>
<pubDate>Tue, 12 Aug 2025 12:14:00 GMT</pubDate>
<description>Secured over $111 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by over $71 million in committed capital from Medtronic and LigandAchieved multiple FDA regulatory milestones: Breakthrough Device Designation for AVIM therapy; approval for expanded BACKBEAT study enrollment criteria, and IDE approval for a U.S. pivotal Virtue SAB trial versus commercially available paclitaxel-coated balloon NEW HOPE,</description>
</item>
<item>
<title>Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-announces-rollout-fda-110000674</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-announces-rollout-fda-110000674</guid>
<pubDate>Fri, 08 Aug 2025 11:00:00 GMT</pubDate>
<description>FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study (“BACKBEAT study”), resulting in an estimated more than 24-fold increase in the potentially eligible patient pool as compared to original study protocolExpanded eligibility criteria now include screening of any hypertensive patients who have received or are scheduled to receive a Medtronic Azure™ or Astra™ pacemaker, including device replacements NEW HOPE, Pa., Aug. 08, 2025 (GLO</description>
</item>
<item>
<title>Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings</title>
<link>https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-secures-over-111-110000344</link>
<guid isPermaLink="true">https://6ix.com/company/orchestra-biomed-holdings-inc/news/orchestra-biomed-secures-over-111-110000344</guid>
<pubDate>Tue, 05 Aug 2025 11:00:00 GMT</pubDate>
<description>$56.2 million in proceeds from completed public offering and concurrent private equity purchase by Medtronic and Ligand$55 million in proceeds and funding commitments from royalty-based, non-dilutive investments from Medtronic and LigandProceeds extend expected cash runway into the second half of 2027 and expected to fund completion of enrollment and follow up for the primary endpoint of the BACKBEAT study, as well as substantial enrollment of the Virtue Trial NEW HOPE, Pa., Aug. 05, 2025 (GLOBE</description>
</item>
</channel>
</rss>